Improving immune response in uterine cancer by targeting DNA damage
Targeting replication stress to engage DNA sensing STING pathway derived anti-tumor immunity to improve the therapeutic outcomes in uterine cancer
This study is looking at a new way to help people with recurring uterine cancers by using special treatments that could make their tumors more responsive to the immune system, potentially leading to better results and fewer side effects.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11070315 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat recurrent uterine cancers that are microsatellite stable and mismatch repair proficient. It aims to enhance the effectiveness of existing treatments by targeting replication stress in cancer cells, which can activate the immune system's response against tumors. The study will explore the use of specific inhibitors that target DNA damage checkpoints, potentially transforming 'cold' tumors into 'hot' tumors that are more responsive to immunotherapy. Patients may benefit from improved treatment options that could lead to better outcomes and fewer side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with recurrent microsatellite stable/mismatch repair proficient uterine cancers who have not responded to or cannot tolerate current FDA-approved treatments.
Not a fit: Patients with other types of uterine cancer or those who have already responded well to existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new therapeutic strategies that enhance anti-tumor immunity and improve treatment outcomes for patients with recurrent uterine cancer.
How similar studies have performed: Other research has shown promising results using similar approaches to activate immune responses in tumors, suggesting potential for success in this novel application.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Zhao, Jean — Dana-Farber Cancer Inst
- Study coordinator: Zhao, Jean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.